RG
EW icon

Rathbones Group’s Edwards Lifesciences EW Stock Holding History

Rathbones Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.26M Sell
13,882
-389
-3% -$32.6K ﹤0.01% 347
2026
Q1 		$1.14M Sell
14,271
-2,424
-15% -$200K ﹤0.01% 348
2025
Q4 		$1.42M Sell
16,695
-71,276
-81% -$5.85M 0.01% 331
2025
Q3 		$6.84M Sell
87,971
-40,645
-32% -$3.18M 0.03% 183
2025
Q2 		$10.1M Sell
128,616
-499,459
-80% -$37.2M 0.04% 162
2025
Q1 		$45.5M Sell
628,075
-671,096
-52% -$48M 0.22% 98
2024
Q4 		$96.2M Buy
1,299,171
+15,192
+1% +$1.06M 0.47% 55
2024
Q3 		$84.7M Buy
1,283,979
+363,051
+39% +$26.4M 0.43% 64
2024
Q2 		$85.1M Buy
920,928
+32,422
+4% +$2.87M 0.46% 58
2024
Q1 		$84.9M Buy
888,506
+75,529
+9% +$6.34M 0.49% 52
2023
Q4 		$62M Buy
812,977
+90,025
+12% +$6.26M 0.4% 61
2023
Q3 		$50.1M Buy
722,952
+145,089
+25% +$11.7M 0.36% 65
2023
Q2 		$54.5M Buy
577,863
+36,865
+7% +$3.2M 0.51% 54
2023
Q1 		$44.8M Buy
540,998
+48,481
+10% +$3.81M 0.46% 59
2022
Q4 		$36.7M Buy
492,517
+52,724
+12% +$4.06M 0.41% 64
2022
Q3 		$36.3M Buy
439,793
+8,919
+2% +$858K 0.45% 58
2022
Q2 		$41M Buy
430,874
+28,635
+7% +$2.96M 0.47% 58
2022
Q1 		$47.4M Buy
402,239
+10,101
+3% +$1.13M 0.48% 52
2021
Q4 		$50.8M Buy
392,138
+26,049
+7% +$3.04M 0.49% 55
2021
Q3 		$41.4M Buy
366,089
+49
+0% +$5.59K 0.45% 58
2021
Q2 		$37.9M Buy
366,040
+49,435
+16% +$4.66M 0.42% 60
2021
Q1 		$26.5M Buy
316,605
+82,311
+35% +$6.96M 0.34% 75
2020
Q4 		$21.4M Buy
234,294
+121,929
+109% +$10.1M 0.3% 78
2020
Q3 		$8.97M Buy
112,365
+86,020
+327% +$6.71M 0.15% 95
2020
Q2 		$1.82M Buy
26,345
+21,824
+483% +$1.55M 0.04% 170
2020
Q1 		$284K Buy
+4,521
New +$326K 0.01% 253

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Rathbones Group's EW Position: Q2 2026 in Review

Rathbones Group reduced its Edwards Lifesciences (EW) stake by 2.7% in Q2 2026, selling an estimated $32.6K and leaving 13,882 shares worth $1.26M. The position accounts for ﹤0.01% of the portfolio, ranked #347.

Rathbones Group first reported a position in EW in Q1 2020 and has held it in 26 quarters since. The position peaked at $96.2M in Q4 2024. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Rathbones Group held 13,882 shares of Edwards Lifesciences worth $1.26M as of Q2 2026.
  • Rathbones Group sold 389 Edwards Lifesciences shares in Q2 2026, an estimated $32.6K.
  • Edwards Lifesciences made up ﹤0.01% of Rathbones Group's portfolio in Q2 2026, its #347 holding.
  • Rathbones Group first reported a position in Edwards Lifesciences in Q1 2020 and has held it in 26 quarters since.
  • Rathbones Group's Edwards Lifesciences position peaked at $96.2M in Q4 2024.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Rathbones Group's 13F filing for Q2 2026, filed 23 Jul 2026.